CAR-T Cell Therapy for ALL
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children and the second most frequent acute leukemia in adults. B-cell ALL constitutes approximately 85% of all ALL diagnoses. In Pakistan, ALL represents the most prevalent haematological malignancy presenting to tertiary centres, with AFBMTC receiving the largest national referral volume for haematological malignancies and transplantation. First-line combination chemotherapy achieves complete remission (CR) in \>95% of paediatric patients; however, 15-20% relapse. Outcomes following first relapse are substantially inferior: second-line salvage chemotherapy achieves CR2 in 30-50% of patients, and long-term event-free survival (EFS) after conventional chemotherapy alone is \<10%. Outcomes in adult ALL are even more dismal, with OS at 5 years below 40% even in first CR without allogeneic transplant. Patients with primary refractory ALL or multiply relapsed ALL have an unmet medical need for novel therapeutic approaches. The classical paradigm of chemotherapy followed by allogeneic haematopoietic stem cell transplantation (allo-HSCT) is limited by donor availability, conditioning-related mortality, and inability to achieve remission before transplant.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 5 do 50 lat
- •Potwierdzona białaczka limfoblastyczna B-komórkowa (ALL) z CD19+
- •Choroba, która powróciła przynajmniej drugi raz lub nie reaguje na chemioterapię
- •Potwierdzenie białaczki w badaniu szpiku kostnego w ciągu 3 miesięcy przed włączeniem
- •Prawidłowa funkcja nerek, wątroby, serca i płuc
- •Wystarczająca liczba komórek do zebrania przed leczeniem
- •Oczekiwana długość życia co najmniej 12 tygodni
Simplified criteria — AI translation
Trial details
- Minimum age
- 5 Years
- Maximum age
- 50 Years
- Last updated (source)
- July 10, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
National University of Medical Sciences, Clinical Trial Unit
Rawalpindi, Pakistan
Trial contact
Nadia Sial, Ph.D
Maryam Khan, MBBS, MRCP(UK), FCPS (Cl Haem)
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.